The global Interstitial Lung Disease Market is estimated to be valued at US$ 1790.83 Mn in 2023 and is expected to exhibit a CAGR of 6.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Common symptoms include dry cough and shortness of breath on exertion. ILDs are often progressive and can lead to severe respiratory failure. The treatment of ILDs aims to slow disease progression and relieve symptoms.
Market key trends:
One of the key trends seen in the Interstitial Lung Disease market is the increasing focus on development of biologics. Emerging biologics target specific pathways implicated in the pathogenesis of ILD and show promising preclinical and early clinical trial results. Compared to generic drugs, biologics have novel mechanisms of action and ability to selectively modulate certain pathways. They are thus expected to revolutionize the treatment landscape of ILDs by arresting or reversing disease progression with fewer side effects. Leading drug makers are investing heavily in development of new biologics for fibrotic lung diseases like idiopathic pulmonary fibrosis and are conducting large phase III trials. If successful, biologics will capture a major share of the lucrative ILD market worldwide.
Segment Analysis
The Global Interstitial Lung Disease Market Size can be segmented based on type, treatment, and end user. Based on type, the market is segmented into idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia, cryptogenic organizing pneumonia, acute interstitial pneumonia, desert rheumatism associated lung disease and others. Among these, the idiopathic pulmonary fibrosis segment dominated the market in 2023 due to the high prevalence and lack of cure. Based on treatment, the market is divided into drug treatment, oxygen therapy, lung transplant and others. The drug treatment segment holds the largest share as it is the first line therapy for most interstitial lung diseases. Based on end user, the market is bifurcated into hospitals, specialty clinics and research & academic institutes. Hospitals dominated the segment due to availability of advanced treatment facilities.
Key Takeaways
The global interstitial lung disease market is expected to witness high growth, exhibiting CAGR of 6.5% over the forecast period, due to increasing ageing population and rising awareness about lung diseases.
Regional analysis
North America dominated the interstitial lung disease market in 2023 due to increasing prevalence of chronic respiratory diseases, developed healthcare infrastructure and availability of sophisticated treatments in the region. Asia Pacific is expected to grow at the fastest rate during the forecast period owing to rising pollution levels, smoking rates and improving healthcare facilities.
Key players
Key players operating in the interstitial lung disease market are MSD (Merck), Liminal Biosciences, Glenmark Pharma, J.B. Chemicals & Pharmaceuticals, Boehringer Ingelhim International GmbH, F. Hoffmann-La Roche Ltd, Inc., and Cipla. MSD is the market leader with wide product portfolio and global presence. Liminal Biosciences is emerging as prominent player focusing on orphan lung diseases.
Read Our More Blogs : https://www.rapidwebwire.com/interstitial-lung-disease-market-size-share-analysis-2023-2030/
Comments
0 comment